Arginase, a Possible Therapeutic Target in Prostate Cancer

Abstract

With increasing populations, the prevalence of prostate cancer increases. In the future, a significant public health crisis can be recognized in the present incidence of prostate cancer. In order to counter this, markers should be established for the advanced diagnosis and treatment of the illness prognosis. The cells dominate our immune system and grow into a detectable tumour, causing cancer. At this stage in the body, several processes are dominated, governed and deregulated by the tumour. In most cases, immune response undertakes measures by limiting the availability of Arginine. In this context it is fascinating to examine how the levels of Arginine fluctuate with the severity of the disease and the levels of Arginase and NO. Substances and methods: In 25 beginning phases and 25 advanced stage of the prostate cancer patients and compared to 25 healthy controls, 5 ml of the blood were taken and tested for serum levels of Arginina, and nitric oxide. A substantial reduction in arginine (p<0.001) found was detected. In Arginase and levels a substantial increase (p<0.001) was detected. Conclusion: Increased Arginase levels are linked to the illness progression and the result lowers as Arginase uses most phases. Therefore, Arginase inhibition can be promising therapeutic target in prostate cancer.